However, due to the highly specific cell-type specificity of CaSR regulation and signaling, the pharmacotherapy of cardiovascular diseases that directly target the CaSR may have adverse effects on other tissues, such as kidney injury. The gene discussed is CASR; the disease is cardiovascular disorder.